Ariel Investments, an investment management company, released its “Ariel Global Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Ariel Global Fund delivered solid results in 2025, rising +23.30% for the year and outperforming both the MSCI ACWI and MSCI ACWI Value indices, although it lagged benchmarks in the fourth quarter with a +2.88% return versus +3.29% and +3.66%, respectively, for the indexes. The quarter unfolded against a constructive global backdrop, as moderating inflation, easing financial conditions, and resilient corporate earnings supported equities, with strength led by U.S. mega-cap technology stocks, improving conditions in Europe and Japan, and a strong full-year rebound in China. Performance was driven primarily by stock selection, with gains in financials and information technology offset by weakness in consumer discretionary and healthcare holdings, while several individual positions faced short-term pressures from higher costs, restructuring charges, or softer demand. Looking ahead, management remains optimistic on international equities, citing improving corporate fundamentals, supportive policy environments, and attractive valuations relative to growth prospects, while emphasizing that increasing market dispersion and a broadening of leadership beyond U.S. mega-cap stocks create a favorable environment for active, bottom-up stock selection focused on companies with strong balance sheets, durable earnings, and long-term structural growth drivers. In addition, you can check the Fund’s top 5 holdings for its best picks for 2025.
In its fourth-quarter 2025 investor letter, Ariel Investments’ Global Fund highlighted stocks like Fresenius Medical Care AG (NYSE:FMS). Fresenius Medical Care AG (NYSE:FMS) is a global healthcare company specializing in dialysis products and services, providing life-sustaining treatment to patients with chronic kidney failure worldwide. The one-month return of Fresenius Medical Care AG (NYSE:FMS) was -5.16% while its shares traded between $20.95 and $30.46 over the last 52 weeks. On March 30, 2026, Fresenius Medical Care AG (NYSE:FMS) stock closed at approximately $22.21 per share, with a market capitalization of about $12.80 billion.
Ariel Investments’ Global Fund stated the following regarding Fresenius Medical Care AG (NYSE:FMS) in its Q4 2025 investor letter:
“Fresenius Medical Care AG (NYSE:FMS), the Germany-based global leader in kidney dialysis services and products, traded lower on mixed quarterly results. While the company delivered organic growth across all segments, earnings were impacted by continued restructuring and portfolio optimization costs. With profitability trending higher and strong cash generation supporting balance sheet deleveraging, we view Fresenius as attractively positioned from a risk/reward perspective.”
Fresenius Medical Care AG (NYSE:FMS)is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 12 hedge fund portfolios held Fresenius Medical Care AG (NYSE:FMS) at the end of the fourth quarter, which was 8 in the previous quarter. While we acknowledge the risk and potential of Fresenius Medical Care AG (NYSE:FMS) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Fresenius Medical Care AG (NYSE:FMS) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Fresenius Medical Care AG (NYSE:FMS) and shared the list of best German stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
